HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

VapoCool Adds Menthol To P&G's DayQuil, NyQuil Cough/Cold Remedies

This article was originally published in The Pink Sheet & The Rose Sheet

Executive Summary

Liquid and caplet DayQuil and NyQuil Severe with VapoCool, also offered in cold/flu formulations, are on retailer shelves ready for the cold season. P&G also increases amount of menthol in its Vicks Severe Medicated Drops sore throat lozenges to mark 125th anniversary Vicks line introduction.

You may also be interested in...



P&G Stretches ZzzQuil Sleep Brand Into Supplement Space With PureZzzs

P&G will launch Vicks ZzzQuil PureZzzs in late February as a drug-free, melatonin-based sleep aid, CFO Jon Moeller says. P&G hopes to reach $4.5bn in e-commerce sales in 2018, up from $3bn in 2017.

Perrigo Steers Through Transportation Obstacles, Soaring Shipping Costs From COVID-19

Perrigo largely has resolved distribution problems, but shipping freight costs still are much higher than pre-pandemic and it must divest a wound-care brand before US regulators sign off on acquisition of HRA Pharma, says CEO Murray Kessler during J.P. Morgan conference.

In Flip Of Bausch Health’s Planned Order For IPOs, Bausch + Lomb Registration Comes Before Solta

“We are positioned to move forward with either the Bausch + Lomb or Solta IPO quickly when market conditions are right for each of them,” CEO Joseph Papa says at J.P. Morgan conference, but the firm’s “next step” in the process of separating the two businesses was filing with the SEC an IPO registration for Bausch + Lomb.

Topics

Related Companies

UsernamePublicRestriction

Register

RS122706

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel